UCB's Global Corporate Website

Seletalisib (UCB5857)

 

Back to the Clinical Study Index

 

Disease area
studied
Abbreviated title Phase Study ID Registry database Study results Plain language summary Publication (if available)
APDS An Open-Label, Exploratory, Multicenter, Extension Study to Evaluate the Long-Term Safety, Tolerability, Pharmacokinetics and Efficacy of UCB5857 in Subjects with Activated Phosphoinositide 3 Kinase (PI3K) Delta Syndrome (APDS) Phase 3 APD003
Terminated
 
2015-005541-30

LINK
   
Sjogren´s Syndrome  A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study to Evaluate the Efficacy of UCB5857 Over 12 Weeks in Subjects With Primary Sjorgen's Syndrome Phase 2 SS0004
Terminated
NCT02610543
2014-004523-51
 
  Juarez M., Diaz N., Johnston G.I., Nayar S., Payne A. et al. heumatology (Oxford) 2020 [ePub]